93 related articles for article (PubMed ID: 15230628)
1. Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept.
Drugs R D; 2004; 5(4):218-9. PubMed ID: 15230628
[TBL] [Abstract][Full Text] [Related]
2. Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.
Panickar KS
Curr Opin Mol Ther; 2010 Dec; 12(6):780-9. PubMed ID: 21154169
[TBL] [Abstract][Full Text] [Related]
3. Corticorelin acetate injections for the treatment of peritumoral brain edema.
Moliterno JA; Henry E; Pannullo SC
Expert Opin Investig Drugs; 2009 Sep; 18(9):1413-9. PubMed ID: 19678803
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
Villalona-Calero MA; Eckardt J; Burris H; Kraynak M; Fields-Jones S; Bazan C; Lancaster J; Hander T; Goldblum R; Hammond L; Bari A; Drengler R; Rothenberg M; Hadovsky G; Von Hoff DD
Ann Oncol; 1998 Jan; 9(1):71-7. PubMed ID: 9541686
[TBL] [Abstract][Full Text] [Related]
5. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
[TBL] [Abstract][Full Text] [Related]
6. Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models.
Gamez I; Ryan RP; Reid LD; Routt SM; Hollister BA
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1415-22. PubMed ID: 20809121
[TBL] [Abstract][Full Text] [Related]
7. The use of corticotropin releasing factor (CRE) for the treatment of post-operative cerebral edema. A preliminary study.
Wen XL; Guo ZG; Datta N
Chin Med J (Engl); 1991 Jul; 104(7):557-61. PubMed ID: 1879218
[TBL] [Abstract][Full Text] [Related]
8. Corticotropin-releasing factor decreases vasogenic brain edema.
Tjuvajev J; Uehara H; Desai R; Beattie B; Matei C; Zhou Y; Kreek MJ; Koutcher J; Blasberg R
Cancer Res; 1996 Mar; 56(6):1352-60. PubMed ID: 8640825
[TBL] [Abstract][Full Text] [Related]
9. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy.
Recht L; Mechtler LL; Wong ET; O'Connor PC; Rodda BE
J Clin Oncol; 2013 Mar; 31(9):1182-7. PubMed ID: 23382470
[TBL] [Abstract][Full Text] [Related]
10. Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models.
Gamez I; Ryan RP; Keir ST
Anticancer Res; 2010 Dec; 30(12):5037-42. PubMed ID: 21187487
[TBL] [Abstract][Full Text] [Related]
11. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
12. Intravenous application of ovine and human corticotropin releasing factor (CRF): ACTH, cortisol and CRF levels.
Stalla GK; Hartwimmer J; Schopohl J; von Werder K; Müller OA
Neuroendocrinology; 1986; 42(1):1-5. PubMed ID: 3001563
[TBL] [Abstract][Full Text] [Related]
13. The effects of human corticotrophin releasing factor on motor and cognitive deficits after impact acceleration injury.
Beaumont A; Marmarou C; Marmarou A
Neurol Res; 2000 Oct; 22(7):665-73. PubMed ID: 11091970
[TBL] [Abstract][Full Text] [Related]
14. Arginine vasopressin is a much more potent stimulus to ACTH release from ovine anterior pituitary cells than ovine corticotropin-releasing factor. 1. In vitro studies.
Familari M; Smith AI; Smith R; Funder JW
Neuroendocrinology; 1989 Aug; 50(2):152-7. PubMed ID: 2550836
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis.
Trainer PJ; Faria M; Newell-Price J; Browne P; Kopelman P; Coy DH; Besser GM; Grossman AB
J Clin Endocrinol Metab; 1995 Feb; 80(2):412-7. PubMed ID: 7852498
[TBL] [Abstract][Full Text] [Related]
16. Effects of corticotropin releasing factor and growth hormone releasing factor on pituitary hormone secretion in patients with congenital thyrotropin deficiency. Abnormal response of growth hormone to corticotropin releasing factor.
Hayashizaki Y; Miyai K; Onishi T; Kumahara Y
Horm Metab Res; 1986 Dec; 18(12):849-53. PubMed ID: 3102339
[TBL] [Abstract][Full Text] [Related]
17. Effect of the long-term administration of corticotropin-releasing factor on the pituitary-adrenal and pituitary-gonadal axis in the male rat.
Rivier C; Vale W
J Clin Invest; 1985 Feb; 75(2):689-94. PubMed ID: 2982917
[TBL] [Abstract][Full Text] [Related]
18. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.
Behan DP; De Souza EB; Lowry PJ; Potter E; Sawchenko P; Vale WW
Front Neuroendocrinol; 1995 Oct; 16(4):362-82. PubMed ID: 8557170
[TBL] [Abstract][Full Text] [Related]
19. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man.
Lamberts SW; Verleun T; Oosterom R; de Jong F; Hackeng WH
J Clin Endocrinol Metab; 1984 Feb; 58(2):298-303. PubMed ID: 6319446
[TBL] [Abstract][Full Text] [Related]
20. The effect of human corticotrophin releasing factor on the formation of post-traumatic cerebral edema.
Beaumont A; Marmarou A
Acta Neurochir Suppl; 1998; 71():149-52. PubMed ID: 9779170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
